Eqis Capital Management Inc. lowered its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 13.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,444 shares of the company’s stock after selling 2,490 shares during the quarter. Eqis Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $106,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. DNB Asset Management AS increased its stake in Teva Pharmaceutical Industries by 10.9% in the 2nd quarter. DNB Asset Management AS now owns 85,262 shares of the company’s stock valued at $787,000 after buying an additional 8,379 shares during the last quarter. Sanders Morris Harris LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $76,000. Exane Derivatives grew its position in shares of Teva Pharmaceutical Industries by 470.2% during the 2nd quarter. Exane Derivatives now owns 53,093 shares of the company’s stock valued at $490,000 after acquiring an additional 43,782 shares during the period. Xact Kapitalforvaltning AB grew its position in shares of Teva Pharmaceutical Industries by 37.2% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 39,100 shares of the company’s stock valued at $361,000 after acquiring an additional 10,600 shares during the period. Finally, Bridge Creek Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 9.3% during the 2nd quarter. Bridge Creek Capital Management LLC now owns 30,425 shares of the company’s stock valued at $281,000 after acquiring an additional 2,600 shares during the period. Hedge funds and other institutional investors own 54.10% of the company’s stock.
TEVA has been the subject of a number of research reports. Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They set a “neutral” rating for the company. Royal Bank of Canada reissued a “hold” rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 8th. Cowen set a $9.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Wednesday, August 7th. SunTrust Banks reduced their target price on shares of Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a research report on Thursday, August 8th. Finally, Wells Fargo & Co cut their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a report on Monday, September 30th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $10.83.
Teva Pharmaceutical Industries stock opened at $10.72 on Tuesday. The firm’s fifty day moving average price is $8.47 and its 200-day moving average price is $8.49. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89. The stock has a market cap of $11.17 billion, a P/E ratio of 3.83, a price-to-earnings-growth ratio of 1.10 and a beta of 1.73. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $6.07 and a fifty-two week high of $22.29.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by ($0.02). The company had revenue of $4.26 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Lock-Up Period Expiration
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.